Anti-inflammatory compounds
OwnerSalomon Amarinventor
Life of this patent
Estimating the term…
Abstract
Synthetic kava analog compounds of formula I are disclosed. Specifically, kava analogs of the structural type 3-oxoclclohex-1-en-1-yl benzoates, and corresponding benzamides are disclosed. The compounds of the within invention are useful, in the inhibition of cytokine TNF-α, the management of chronic inflammation such as but not limited to Porphyromonas gingivalis induced periodontitis, and in infective arthritis, either as compounds, pharmaceutically acceptable salts (when appropriate), pharmaceutical composition ingredients, whether or not in combination with other anti-inflammatory active pharmaceutical ingredients. Methods of treating chronic inflammation such as periodontitis and infective arthritis are also disclosed.
Claims13
A method for treating inflammation comprising administration of an active pharmaceutical composition comprising a compound wherein the compound is (i) 5,5-dimethyl-3-oxocyclohex-1-en-1-yl 4-methylbenzoate, (ii) 3-oxocyclohex-1-en-1-yl 4-methylbenzoate, (iii) 5,5-dimethyl-3-oxocyclohex-1-en-1-yl 4-methoxybenzoate, (iv) 5,5-dimethyl-3-oxocyclohex-1-en-1-yl 4-fluorobenzoate, (v) 5,5-dimethyl-3-oxocyclohex-1-en-1-yl 3,4-difluorobenzoate, (vi) 5,5-dimethyl-3-oxocyclohex-1-en-1-yl benzoate, (vii) 4-(ethoxycarbonyl)-5,5-dimethyl-3-oxocyclohex-1-en-1-yl 4-methoxybenzoate, (viii) 4-(ethoxycarbonyl)-5,5-dimethyl-3-oxocyclohex-1-en-1-yl benzoate, (ix) 4-(ethoxycarbonyl)-5,5-dimethyl-3-oxocyclohex-1-en-1-yl 3,4-difluorobenzoate, (x) 5,5-dimethyl-3-oxocyclohex-1-en-1-yl 3,4-dimethoxybenzoate, (xi) 4-(ethoxycarbonyl)-5,5-dimethyl-3-oxocyclohex-1-en-1-yl 4-(benzyloxy)benzoate, (xii) 4-(ethoxycarbonyl)-5,5-dimethyl-3-oxocyclohex-1-en-1-yl 4-ethoxybenzoate, or a pharmaceutically acceptable salt thereof.
A method for treating inflammation comprising administration of an active pharmaceutical composition comprising a compound wherein the compound is 5,5-dimethyl-3-oxocyclohex-1-en-1-yl benzoate, or a pharmaceutically acceptable salt thereof.
A method for treating inflammation comprising administration of an active pharmaceutical composition comprising a compound wherein the compound is 5,5-dimethy 1-3-oxocyclohex-1-en-y 1 4-methylbenzoate, or a pharmaceutically acceptable salt thereof.
A method for treating inflammation, wherein the inflammation is associated with periodontal disease and/or periodontal bone loss, comprising administration of an active pharmaceutical composition comprising a compound wherein the compound is (i) 5,5-dimethyl-3-oxocyclohex-1-en-1-yl 4-methylbenzoate, (ii) 3-oxocyclohex-1-en-1-yl 4-methylbenzoate, (iii) 5,5-dimethyl-3-oxocyclohex-1-en-1-yl 4-methoxybenzoate, (iv) 5,5-dimethyl-3-oxocyclohex-1-en-1-y1 4-fluorobenzoate, (v) 5,5-dimethyl-3-oxocyclohex-1-en-1-yl 3,4-difluorobenzoate, (vi) 5,5-dimethyl-3-oxocyclohex-1-en-1-yl benzoate, (vii) 4-(ethoxycarbonyl)-5,5-dimethyl-3-oxocyclohex-1-en-1-yl 4-methoxybenzoate, (viii) 4-(ethoxycarbonyl)-5,5-dimethyl-3-oxocyclohex-1-en-1-yl benzoate, (ix) 4-(ethoxycarbonyl)-5,5-dimethyl-3-oxocyclohex-1-en-1-yl 3,4-difluorobenzoate, (x) 5,5-dimethyl-3-oxocyclohex-1-en-1-yl 3,4-dimethoxybenzoate, (xi) 4-(ethoxycarbonyl)-5,5-dimethyl-3-oxocyclohex-1-en-1-yl 4-(benzyloxy)benzoate, (xii) 4-(ethoxycarbonyl)-5,5-dimethyl-3-oxocyclohex-1-en-1-yl 4-ethoxybenzoate, (xiii) N-(5,5-dimethyl-3-oxocyclohex-1-en-1-yl) benzamide, (xiv) N-(5,5-dimethyl-3-oxocyclohex-1-en-1-yl)-4-methylbenzamide, (xv) N-(5,5-dimethyl-3-oxocyclohex-1-en-1-yl)-4-methoxybenzamide, or a pharmaceutically acceptable salt thereof.
A method for treating inflammation, wherein the inflammation is associated with rheumatoid arthritis, comprising administration of an active pharmaceutical composition comprising a compound wherein the compound is (i) 5,5-dimethyl-3-oxocyclohex-1-en-1-yl 4-methylbenzoate, (ii) 3-oxocyclohex-1-en-1-yl 4-methylbenzoate, (iii) 5,5-dimethyl-3-oxocyclohex-1-en-1-yl 4-methoxybenzoate, (iv) 5,5-dimethyl-3-oxocyclohex-1-en-1-yl 4-fluorobenzoate, (v) 5,5-dimethyl-3-oxocyclohex-1-en-1-yl 3,4-difluorobenzoate, (vi) 5,5-dimethyl-3-oxocyclohex-1-en-1-yl benzoate, (vii) 4-(ethoxycarbonyl)-5,5-dimethyl-3-oxocyclohex-1-en-1-yl 4-methoxybenzoate, (viii) 4-(ethoxycarbonyl)-5,5-dimethyl-3-oxocyclohex-1-en-1-yl benzoate, (ix) 4-(ethoxycarbonyl)-5,5-dimethyl-3-oxocyclohex-1-en-1-yl 3,4-difluorobenzoate, (x) 5,5-dimethyl-3-oxocyclohex-1-en-1-yl 3,4-dimethoxybenzoate, (xi) 4-(ethoxycarbonyl)-5,5-dimethyl-3-oxocyclohex-1-en-1-yl 4-(benzyloxy)benzoate, (xii) 4-(ethoxycarbonyl)-5,5-dimethyl-3-oxocyclohex-1-en-1-yl 4-ethoxybenzoate, (xiii) N-(5,5-dimethyl-3-oxocyclohex-1-en-1-yl) benzamide, (xiv) N-(5,5-dimethyl-3-oxocyclohex-1-en-1-yl)-4-methylbenzamide, (xv) N-(5,5-dimethyl-3-oxocyclohex-1-en-1-yl)-4-methoxybenzamide, or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.